Table 3.
Comparison based on taking LTRA therapy 6 months after starting biological therapy.
| T1 TIME | |||
|---|---|---|---|
| LTRA Yes (n = 15) | LTRA No (n = 24) | p Value | |
| FeNO 50, ppb m ± sd | 30.83 ± 24.30 | 88.93 ± 77.96 | 0.009 |
| EOS, cells/μL median (IQ 25–75) | 150.00 (125.00 380.00) | 100.00 (65.00–265.00) | 0.201 |
| IgE, KU/L median (IQ 25–75) | 555.00 (400.00–700.00) | 215.00 (132.00–324.00) | 0.067 |
| FEV1, m ± sd % predicted | 80.34 ± 19.20 | 87.58 ± 18.59 | 0.305 |
| FVC, m ± sd % predicted | 94.97 ± 23.91 | 98.64 ± 27.07 | 0.707 |
| ACT, score m ± sd | 20.13 ± 4.06 | 22.00 ± 4.26 | 0.193 |
| ACQ, score m ± sd | 1.12 ± 0.88 | 0.94 ± 0.81 | 0.663 |
| Need of inhaled reliever medication, % | 20.0 | 20.0 | 0.709 |
| OCS yes, % | 40.0 | 47.6 | 0.456 |
| Average dose of OCS, mg m ± sd | 3.55 ± 4.99 | 4.19 ± 8.30 | 0.503 |
| Adherence to therapy, % | 90.0 | 100.0 | 0.500 |
| WBCs, cells/μL median (IQ 25–75) | 8950.00 (7000.00–10,900.00 | 7100.00(6590–9275) | 0.555 |
| OCS course, n m ± sd | 0.53 ± 1.34 | 0.69 ± 1.79 | |
| Bronchial exacerbation/6 months n m ± sd | 0.41 ± 0,77 | 0.53 ± 0.80 | 0.639 |
| antibiotic courses/6 months n m ± sd | 0.20 ± 0.41 | 0.28 ± 0.51 | 0.584 |
| Number of hospitalizations/6 months n m ± sd | 0.10 ± 0.20 | 0.50 ± 0.70 | 0.052 |
| Unplanned visits to specialists/6 months n m ± sd | 1.26 ± 0.07 | 2.40 ± 1.17 | 0.003 |
FeNO: exhaled nitric oxide; EOS: blood eosinophilia; FEV1: forced expiratory volume in the 1st second; FVC: forced vital capacity; IgE: immunoglobulin E; VR: residual volume; ACT: asthma control test; ACQ: asthma control questionnaire; OCS: oral corticosteroid; WBCs: white blood cells; LTRA: leukotriene receptor antagonist.